Abbott Shares Jump After Approval For Diabetes Monitor; Competitor DexCom Crashes On Surprise News

Abbott shares jump after approval for diabetes monitor; competitor DexCom crashes on surprise news

Abbott shares jump after approval for diabetes monitor; competitor DexCom crashes on surprise news

Abbott Laboratories stock jumped after the Food and Drug Administration approved the company's FreeStyle Libre glucose monitoring system, more than a year earlier than Wall Street anticipated.
While Abbott shares jumped 4 percent Wednesday after the surprise FDA call, competitor DexCom saw its shares crater by more than 36 percent.
Abbott's Libre is the first glucose monitoring system that adult diabetic patients can use to make treatment decisions without using a fingertip blood system. Analysts at J.P. Morgan say Abbott's aggressive distribution strategy has "the five largest pharmacies" ready to begin selling the device in the U.S. as early as December.
J.P. Morgan, which downgrades shares of DexCom to neutral from buy on the news, also said Abbott's pricing for the device is "even more aggressive than our expectations." Abbott will charge an effective rate of around $4 per day for Libre, lower than the $6 analysts at J.P. Morgan anticipated.
DexCom is no longer the sole competitor in manufacturing glucose monitoring systems, J.P. Morgan said. With new, low-priced competition, the firm says DexCom now must innovate under pressure to discount its hardware, which previously made margins of 45 to 50 percent per device. But all is not lost for DexCom, as J.P. Morgan says its "technology is superior to Libre."
"Before long, DexCom should be able to surpass the Libre offering," J.P. Morgan said. "But it will be at a lower price point and likely less attractive economics than we've all been expecting."
The technology still has a distance to go before widespread adoption, accord Continue reading

Rate this article
Total 1 ratings
Humana makes strategic investment in connected diabetes management company Livongo

Humana makes strategic investment in connected diabetes management company Livongo

Livongo, the mobile-enabled diabetes management company, has raised a strategic investment from Humana to support the company’s growth. Update: Humana invested $5 million in Livongo.
Prior to this investment, Livongo has raised at least $82.5 million to date. Just last month, the company announced a $44.5 million raise. Existing investors include Merck Global Health Innovation Fund, Cowen Private Investments, Sapphire Ventures, Zaffre Investments, the investment arm of Blue Cross Blue Shield of Massachusetts, Wanxiang America Corporation, General Catalyst Partners, Kleiner Perkins Caufield & Byers (KPCB), and DFJ Venture.
“Our industry’s continued shift to value-based care provides impetus for everyone to work together to reinvent healthcare, and our partnership with Livongo Health is a direct example of how collaboration between companies can work to move the needle,” Sarah Ahmad, VP and Head of Innovation for consumer health solutions at Humana, said in a statement.
Livongo Health’s offering, called Livongo for Diabetes, consists of connected devices, a smart cloud, and a virtual care team. The device, called In Touch, serves as both a connected glucometer and a pedometer and will allow easy sharing of the data. It’s a standalone device with a color touchscreen that is cellular-connected. The offering also offers unlimited test strips at no extra charge.
Livongo CEO Glen Tullman told MobiHealthNews last month that the company will use some of the funds from its most recent round to hire people for operations to handle growth — Livongo grew from 5,000 users l Continue reading

Private Equity-Like Fund Aims to Speed Up Diabetes Research

Private Equity-Like Fund Aims to Speed Up Diabetes Research

Dave Johnson says his immediate reaction to his daughter’s diagnosis of Type 1 diabetes at age 4 was typical of any father’s.
“It was my baby girl, and my response was I’m going to fix it or pay someone to fix it,” said Mr. Johnson, president and chief executive of the hotel management company Aimbridge Hospitality. “I dove in, spoke to some smart people. But then, I was hit between the eyes that there wasn’t a lot that I was going to be able to do.”
That was 22 years ago, and what he did do was volunteer with gusto, organizing fund-raisers in the Dallas area where he lived and working his way up to membership on the executive committee of the international board of the Juvenile Diabetes Research Foundation, the main nonprofit group making grants and evaluating research on the disease.
But recently, Mr. Johnson did something that appealed to his business side: He and his wife gave $1 million to a new nonprofit organization, the foundation’s T1D Fund, which invests in companies doing research into Type 1 diabetes. Any financial returns are used to make more investments.
“The fund is extremely transparent and crystal clear in its mission,” Mr. Johnson said. “We have a quarterly call and get updates when we’re making investments. It’s run similar to a for-profit.”
Structured like a private equity fund, the T1D Fund has a minimum donation of $500,000. The fund, which received $32 million in seed funding from the foundation, has a goal of reaching $80 million. It already has $55 million.
Type 1 diabetes is an autoimmune disease that attacks the panc Continue reading

Pharmaceutical giant Novo Nordisk to invest £115m in a new UK drug research centre in post-Brexit 'vote of confidence'

Pharmaceutical giant Novo Nordisk to invest £115m in a new UK drug research centre in post-Brexit 'vote of confidence'

Danish pharmaceutical giant Novo Nordisk is to invest about £115m over 10 years in a new research centre in Oxford, in a move described by the government as a “vote of confidence” in post-Brexit Britain.
About 100 scientists will work at the centre, investigating new approaches to treating type-2 diabetes.
David Gauke, chief secretary to the Treasury, said that the move was a “vote of confidence in the UK’s position as a world leader in science and research,” according to the BBC.
Novo Nordisk’s executive vice-president and chief science officer Mads Thomsen said Britain’s vote to leave the EU was “unfortunate” but should not affect the collaboration between Oxford and the company.
“Obviously we think the Brexit decision was unfortunate. That being said, Oxford University has been around for 800 years so the academic excellence and our company's ability to turn that into medicines hasn't really changed,” Mr Thomsen told the BBC.
John Bell, a medicine professor at Oxford, said the new set-up, which will allow for daily interactions between academic and industrial scientists, underlined the importance of sharing research and cutting-edge science across sectors.
The UK’s decision to leave the EU has raised concerns in the science sector over a potential gap in funding and sparked concerns amongst drugmakers over future regulation.
The European Medicines Agency, a body based in London and responsible for the scientific evaluation and safety monitoring of medicines, warned it is likely to leave after Brexit.
Mr Thomsen told the BBC: “We are very happy Continue reading

Experts Weigh In On Ketogenic Diet for Diabetes Type 2

Experts Weigh In On Ketogenic Diet for Diabetes Type 2

Ketogenic diet has taken us by the wind in the recent years. There are numerous resources available online for people who are considering going on one.
A ketogenic diet, in very simple terms, is a very low-carb diet. It has been claimed that going on a ketogenic diet is beneficial for people seeking to lose weight and to improve their health. This probably sounds very charming to a person with diabetes who is looking to lose excess weight and to improve their overall general health to avoid or prevent any diabetes related complications.
But, is it really worth all the hype it has generated?
For someone who has diabetes, a healthy and nutritional lifestyle is extremely important. Though lowering the consumption of carbs from your diet can aid you, is it actually recommended to restrict yourself to a very low carb diet if you have diabetes?
We can’t claim to know but we reached out to respected experts who have shared their thoughts on the diet and whether they recommend it to their patients.
Read on to find out whether or not you could benefit from going on a Ketogenic diet.
1. Gina Keatley, CDN
I would not recommend the ketogenic diet to any patients other than those suffering with epilepsy. The proper ratio of fat to protein to carbohydrate calories (80-15-5) is extremely difficult to maintain over any period of time. In many research studies over half of the participants drop out of studies before they have completed due to this difficulty and in other studies the researchers do not get institutional approval for such a strict limit of carbohydrates and use one with far Continue reading

No more pages to load

Popular Articles

  • Diabetes monitoring company Dexcom partners with Fitbit, but Apple Watch users not abandoned

    – A + After praising the Apple Watch earlier in the year, glucose monitoring software company Dexcom has forged a partnership with Fitbit to integrate the technology into the Ionic smartwatch —but the monitoring featured in the Fitbit device may appear on the Apple Watch with watchOS 4. With a software update in 2018, the Fitbit Ionic will show a user's date from the G5 mobile sensor. Data wil ...

  • Nick Jonas Talks His First Decade with Diabetes, and Partnering with Dexcom

    Nick Jonas is no longer the teenage boy band star with a squeaky clean image. Enter th e new Nick, now in his early 20s with a grittier edge, and a lot is changing for him and his fans. In the past year or so, Nick's branched out on his own as an artist, added more adult-oriented TV and movie appearances to his acting resume, and just recently announced he's partnering with singer friend Demi Lova ...

  • Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes | Journal of the Endocrine Society | Oxford Academic

    As the accuracy of continuous glucose monitoring (CGM) devices has improved and the benefits are better understood, their use has greatly increased. For patients with diabetes, CGM does more than provide additional data points; it uses trend arrow data to give context to current glucose values. With this level of insight, real-time CGM (rtCGM) has been demonstrated to improve glycemic control wi ...

  • Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients - Jan 4, 2018

    Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients - CMS reimbursement provides opportunity for Medicare patients who meet eligibility criteria to access FreeStyle Libre System - FreeStyle Libre System can replace traditional blood glucose monitoring, eliminating the need for routine fingersticks(1) or any user calibration ABBOTT P ...

  • Medicare, Dexcom G5, & Smartphone Access: Whos to Blame and What Can We Do?

    But the cause for celebration was quickly muted due to the following statement set down by CMS under Miscellaneous : Coverage of the CGM system supply allowance is limited to those therapeutic CGM systems where the beneficiary ONLY uses a receiver classified as DME to display glucose data. If a beneficiary uses a non- DME device (smart phone, tablet, etc.) as the display device, either separate ...

  • A Diabetes Monitor That Spares the Fingers

    For the past year and a half I’ve been buying a medical device from Italy that has improved my life immeasurably. It wasn’t easy: I roped in a good friend who had moved to Milan to buy the device and ship it to me because it wasn’t yet available in the States. And it was expensive: over $1,600 a year. But my black-market purchase helps me manage my Type 1 diabetes without the need to draw bl ...

  • The Apple Watch could one day help monitor diabetes

    Apple apparently has a team working on technology that would enable blood sugar to be monitored by a wearable device. The team – and any progress they've made – are currently top-secret, but as it’s wearable tech it’s safe to assume the device will be an Apple Watch or something similar if the project comes to fruition. The tech giant isn’t by any means the first company to try its hand ...

  • The dogs that smell breath to monitor diabetes

    Guide dogs stop you bumping into things, assistance dogs can pull your clothes out of the washing machine. But medical detection dogs can keep you alive. These dogs have been specially trained to smell several cancer types. Others can gauge the blood sugar levels in diabetics, warn allergic owners away from peanuts, or detect when people with narcolepsy are about to fall asleep. Their sense of sme ...

  • The incredible colour changing tattoos that monitor the blood sugar levels of people with diabetes in real-time

    Researchers have developed a biosensing tattoo ink that reacts to sugar in the blood to help diabetics control their conditions. The colour-changing ink turns the body's surface into an 'interactive display' to alert diabetics when their blood sugar is too low or high. When blood sugar goes up, the glucose sensing ink changes from blue to brown in real-time, a colour change that reverses when bloo ...

Related Articles